Sobi is an international speciality healthcare company dedicated to rare diseases. Our mission is make a real difference to the lives of people with rare diseases by providing innovative therapies.
Our product portfolio focuses primarily on haemophilia, inflammation, and genetic and metabolic disorders. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing.
In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm.
Here in Investors & Media, we present current and past media releases and the latest financial information from Sobi.
If you can’t find what you are looking for, don’t hesitate to contact us. We will be happy to help you find out more about our business and financial performance.